Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timo Joensuu

Showing results (21-30 of 67) with videos related to

Pageof 7
Sort By:
Molecular Therapy Oncolytics|July 11, 2018
Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic ImmunotherapyOtto Hemminki, Minna Oksanen, Kristian Taipale, et al.
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|May 18, 2010
Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancerKauko Saarilahti, Petri Bono, Mikael Kajanti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 10, 2015
Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and TissuesAnniina Koski, Simona Bramante, Anja Kipar, et al.
Acta Oncologica (Stockholm, Sweden)|October 14, 2014
VMAT technique enables concomitant radiotherapy of prostate cancer and pelvic bone metastasesTimo Kiljunen, Aki Kangasmäki, Aili Aaltonen, et al.
Journal of Translational Medicine|August 23, 2013
Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatmentMari Hirvinen, Raita Heiskanen, Minna Oksanen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 11, 2014
Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumorsAnna Kanerva, Anniina Koski, Ilkka Liikanen, et al.
Oncoimmunology|May 8, 2015
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapyIlkka Liikanen, Anniina Koski, Maiju Merisalo-Soikkeli, et al.
Acta Oncologica (Stockholm, Sweden)|July 18, 2022
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trialMiikka Lehtonen, Jorma Sormunen, Tiina Luukkaala, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 3, 2011
Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancerAnniina Koski, Mari Raki, Petri Nokisalmi, et al.
The Journal of Gene Medicine|April 27, 2011
Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patientsMari Raki, Merja Sarkioja, Sophie Escutenaire, et al.
Pageof 7

Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Molecular Therapy Oncolytics|July 11, 2018
Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic ImmunotherapyOtto Hemminki, Minna Oksanen, Kristian Taipale, et al.
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|May 18, 2010
Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancerKauko Saarilahti, Petri Bono, Mikael Kajanti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 10, 2015
Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and TissuesAnniina Koski, Simona Bramante, Anja Kipar, et al.
Acta Oncologica (Stockholm, Sweden)|October 14, 2014
VMAT technique enables concomitant radiotherapy of prostate cancer and pelvic bone metastasesTimo Kiljunen, Aki Kangasmäki, Aili Aaltonen, et al.
Journal of Translational Medicine|August 23, 2013
Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatmentMari Hirvinen, Raita Heiskanen, Minna Oksanen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 11, 2014
Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumorsAnna Kanerva, Anniina Koski, Ilkka Liikanen, et al.
Oncoimmunology|May 8, 2015
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapyIlkka Liikanen, Anniina Koski, Maiju Merisalo-Soikkeli, et al.
Acta Oncologica (Stockholm, Sweden)|July 18, 2022
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trialMiikka Lehtonen, Jorma Sormunen, Tiina Luukkaala, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 3, 2011
Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancerAnniina Koski, Mari Raki, Petri Nokisalmi, et al.
The Journal of Gene Medicine|April 27, 2011
Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patientsMari Raki, Merja Sarkioja, Sophie Escutenaire, et al.
Pageof 7